PDCD1 and neoplasm: Hence, the discovery of co-inhibitory receptors such as Cytotoxic T-Lymphocyte-associated Antigen 4 (CTLA-4) or Programmed Death-1 (PD-1) brought new possibilities to activate immune response against tumor cells using monoclonal antibodies to such co-inhibitory immune checkpoints.